MAAUA: MAAUA 68th Annual Meeting Abstracts - Does ProPSA Predict Biopsy Progression on Active Surveillance?

MAAUA 68th Annual Meeting Abstracts

Does Pro PSA Predict Biopsy Progression on Active Surveillance?
*Jeffrey Tosoian, *Stacy Loeb, *Lori Sokoll, H.B. Carter
Johns Hopkins Hospital, Baltimore, MD

Does ProPSA Predict Biopsy Progression on Active Surveillance?
ABSTRACT
Introduction: Prior studies suggest an association between %proPSA and prostate cancer detection. Less is known about the utility of %proPSA in prostate cancer patients on active surveillance. Thus, our objective was to examine the relationship between %proPSA and biopsy progression among men enrolled in an active surveillance program.
Methods: In 186 men from our institutional active surveillance program, we used longitudinal Cox proportional hazards models to examine the relationship between %proPSA with progression on annual surveillance biopsy. The outcome of interest (progression) was defined in 2 ways: (1) any Gleason pattern 4 or 5, >2 positive biopsy cores, or >50% involvement of any core with cancer; and (2) upgrading to Gleason ≥7.
Results: Overall, 63 (33.9%) men had biopsy progression, including 27 with progression by Gleason score. Longitudinal %proPSA was significantly associated with progression to unfavorable biopsy (p=0.006) and Gleason grade progression (p=0.0008).
Conclusions: %proPSA levels were associated with the risk of short-term biopsy progression among men on active surveillance. Additional study is warranted to identify %proPSA cutpoints for clinical use and to examine the role of %proPSA in conjunction with other markers for monitoring patients enrolled in active surveillance.

Back to Program